[ad_1]
HANGZHOUChina and SHAOXING, China, March 13, 2022 /PRNewswire/ — Ascletis Pharma Inc. (Ascletis, HKEX: 1672) today announces that it has further expanded its ritonavir oral tablet production capacity to approximately 530 million tablets per year, to meet the potential escalation in the domestic and global demands. Ascletis has taken multiple measures for expansion of the annual ritonavir production capacity, including adding additional key equipment at the manufacturing facilities of Ascletis Pharmaceuticals Co., Ltd., a wholly-owned subsidiary of Ascletis.
Ritonavir oral tablet is a pharmacokinetic booster of multiple oral antiviral targeting drugs viral proteases and a component of the approved oral antiviral drug PAXLOVID (Nirmatrelvir 300 mg tablet + ritonavir 100 mg tablet co-administration package).
Ascletis aims to be a global commercial supplier of ritonavir oral tablets. To date, Ascletis owns the only authorized ritonavir oral tablet in Chinawhich has passed bioequivalence study. Ascletis’ ritonavir oral tablet was approved in September 2021 by China National Medical Products Administration (National Medical Products Administration H20213698). Furthermore, Ascletis has submitted marketing authorization applications for ritonavir (100 mg film-coated tablet) in 12 European countries (Germany, France, Irelandthe United Kingdom, Spain
Full story available on Benzinga.com [ad_2]
Source link
